Abstract:Clinical studies have shown that pre-existing tumor-reactive T cells are critically important for effective cancer immunotherapy. Methods to augment the number and functionality of tumor-reactive T cells are therefore vital. Given that cytotoxic CD8 T cell priming requires conventional dendritic cells (cDC), we hypothesized that strategies to enhance cDC functionality in tumors would augment anti-tumor CD8 T cell responses. CD40 and type 1 IFN signaling pathways each promote the cross-presentation function of cDCs to activate CD8 T cells. However, it is unclear whether these pathways are functionally independent and whether their combined activation in tumor cDC leads to higher levels of T cell priming. Using adenovirus vectors, we tested the impact of expression of IFNβ and a chimeric membrane-stable CD40 ligand (MEM40) in syngeneic mouse tumor models. Compared to intratumoral administration of each individual transgene-encoding adenovirus, combined MEM40 + IFNβ expression resulted in the best tumor growth control, highest levels of tumor infiltrating lymphocytes (TILs), and systemic CD8 T cell responses. MEM40 and IFNβ were independently capable of enhancing T cell responses as we found IFNβ in CD40-/- mice and MEM40 in type 1 IFN receptor IFNAR1-/- mice induced a strong T cell response. These results were consistent with a cDC-mediated priming mechanism. Studies with cDC1 deficient BATF3-/- mice revealed a crucial role of this cDC subset in MEM40 + IFNβ induced T cell responses. IFNβ alone and MEM40 + IFNβ triggered increase in lymph node (LN) homing receptor CCR7 expression in cDC1 concurrent with a reduction in cDC1 in tumors and gain in tumor draining LNs. Simultaneously, combined MEM40 + IFNβ combination led to the highest levels of expression of CD80 and CD86 co-stimulatory molecules in both tumor and LN cDC1. Single cell (sc)-RNA sequencing of tumor DCs further showed that MEM40 + IFNβ led to the highest proportion of a recently defined mature/regulatory cDC subset characterized by high expression of CCR7, CD40 and IL12b. Applying these results towards an effective therapeutic modality, we developed a dual-transgene-armed MEM40 + IFNβ expressing conditionally replicative adenovirus (MEM-288) that simultaneously confers tumor-specific oncolysis and promotes tumor antigen release. MEM-288 drives MEM40 + IFNβ expression in freshly resected human lung tumors and generates potent anti-tumor responses as a monotherapy and in combination with immune checkpoint inhibitors. Furthermore, MEM-288 induced enhancement of tumor-reactive TILs and provides a rationale for studies to determine whether MEM-288 pre-treatment generates a superior TIL product for more effective adoptive T cell therapy. Citation Format: Hong Zheng, Scott Antonia, Mark J. Cantwell, Xiaoqing Yu, Amer A. Beg. Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3542.

Adenovirally Delivered IFN-β Exerts Antitumor Effects Through Transient T-lymphocyte Depletion and Ag-specific T-cell Proliferation.

Adenovirus-Mediated Interferon-Gamma Transfer Inhibits Growth Of Transplanted Htlv-I Tax Tumors In Mice

Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice

Adenovirus-Mediated Interferon-Beta Gene Transfer Inhibits Angiogenesis In And Progression Of Orthotopic Tumors Of Human Prostate Cancer Cells In Nude Mice

Adenovirus-mediated Delivery of Interferon-Γ Gene Inhibits the Growth of Nasopharyngeal Carcinoma

Effects of gamma-interferon gene-modified hepatocytes on murine implanted liver carcinoma

Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.

The effect of IFNγ gene modified dendritic cells on T cell proliferation and eradication of tumor cells

Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1

Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.

Dynamic Distribution and Expression in Vivo of the Human Interferon Gamma Gene Delivered by Adenoviral Vector.

Durable Antitumor Response Via an Oncolytic Virus Encoding Decoy-Resistant IL-18

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Immunotherapy of Tumors with Recombinant Adenovirus Encoding Macrophage Inflammatory Protein 3β Induces Tumor-Specific Immune Response in Immunocompetent Tumor-Bearing Mice

Delivery of Interferon Β-Encoding Plasmid Via Lipid Nanoparticle Restores Interferon Β Expression to Enhance Antitumor Immunity in Colon Cancer.

Genetically engineered Newcastle disease virus expressing human interferon-λ1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1/Th2 immune response

Tumor-Suppressive Effect Of Adenovirus-Mediated Inhibitor Of Growth 4 Gene Transfer In Breast Carcinoma Cells In Vitro And In Vivo

Targeting the Tumor Microenvironment with Interferon-Β Bridges Innate and Adaptive Immune Responses.

Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature.

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases